nach oben

PharmacoEconomics

Erschienen in:

01.07.2005 | Correspondence

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK

verfasst von: Eduardo Carracedo-Martínez

Erschienen in: PharmacoEconomics | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Excerpt

An economic evaluation of etoricoxib versus non-selective NSAIDs has been published recently by Moore et al.[1] The decision tree of this study considers the possibility of non-selective NSAIDs plus gastroprotective agents as a decision arm, but not etoricoxib plus gastroprotective agents. …

Moore A, Phillips C, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004; 22 (10): 643–60PubMedCrossRef

Singh G. Understanding NSAID-PPI-COX-2 interrelationships. Drugs Today (Barc) 2004; 40 Suppl. A: 21–4

Kimmey MB, Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-in-flammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004; 19 Suppl. 1: 60–5PubMedCrossRef

Lee MC, Lee S, Suh DC, et al. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea. Curr Med Res Opin 2003; 19 (7): 597–602PubMedCrossRef

Bouee S, Charlemagne A, Fagnani F, et al. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine 2004; 71: 214–20PubMedCrossRef

Ofman JJ, Badamgarav E, Henning JM, et al. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. Am J Med 2004; 116 (12):835–42PubMedCrossRef

Teeling M, Bennett K, Feely J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Br J Clin Pharmacol 2004; 57 (3): 337–43PubMedCrossRef

Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49: 283–92PubMedCrossRef

Titel: Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK
verfasst von: Eduardo Carracedo-Martínez
Publikationsdatum: 01.07.2005
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 7/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523070-00008

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2005

Evaluating health-related quality-of-life studies in paediatric populations

Price differentiation and transparency in the global pharmaceutical marketplace

Discounting health effects in pharmacoeconomic evaluations

The state of patient-reported outcomes in atrial fibrillation

The authors’ reply

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma